| Report ID |
29274 |
| Drug Identification Number |
01927604 |
| Brand name |
MYOCHRYSINE |
| Common or Proper name |
Myochrisine 50mg/1ml |
| Company Name |
SANOFI-AVENTIS CANADA INC |
| Market Status |
CANCELLED POST MARKET |
| Active Ingredient(s) |
GOLD SODIUM THIOMALATE |
| Strength(s) |
50MG |
| Dosage form(s) |
SOLUTION |
| Route of administration |
INTRAMUSCULAR |
| Packaging size |
5 |
| ATC code |
M01CB |
| ATC description |
SPECIFIC ANTIRHEUMATIC AGENTS |
| Reason for shortage |
Shortage of an active ingredient. |
| Anticipated start date |
2017-11-24 |
| Actual start date |
2017-12-01 |
| Estimated end date |
2019-09-30 |
| Actual end date |
2019-06-04 |
| Shortage status |
Resolved |
| Updated date |
2019-06-10 |
| Company comments |
The continued global shortage of Myochrysine is due to manufacturing issues with the active ingredient. Consequently Sanofi has decided to discontinue all three strengths of Myochrysine globally. |
| Health Canada comments |
|
| Tier 3 Status |
No |
| Company contact information |
email: CAINTERNET@sanofi.com
Telephone: 1-800-265-7927 |
